Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2185–2208 of 5,572 matching trials from the live ClinicalTrials.gov search.
Conditions
Agitation, Alzheimer's Disease
Interventions
AVP-923-20, Placebo, AVP-923-30
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
50 Years to 90 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
44
States / cities
Phoenix, Arizona • Sun City, Arizona • Fresno, California + 36 more
Conditions
Cerebral Palsy (CP), Stroke, Spinal Cord Injury, Traumatic Brain Injury, Charcot Marie Tooth Disease (CMT), Spina Bifida
Interventions
Participate in high intensity exercise of at least 20 minutes in 60 minutes session of RPE greater than 6.
Behavioral
Lead sponsor
University of Hartford
Other
Eligibility
8 Years to 99 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
West Hartford, Connecticut
Conditions
Alzheimer Disease, Alzheimer Dementia
Interventions
GENUS device (Active Settings), GENUS device (Sham Settings)
Device
Lead sponsor
Massachusetts Institute of Technology
Other
Eligibility
50 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Cambridge, Massachusetts
Conditions
Alzheimer's Disease
Interventions
Rosiglitazone Extended Release 2mg, Rosiglitazone Extended Release 8mg, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 90 Years
Enrollment
1,468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
49
States / cities
Sun City, Arizona • Tucson, Arizona • Little Rock, Arkansas + 44 more
Conditions
Parkinson's Disease
Interventions
P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),, Placebo, P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),
Drug
Lead sponsor
Pharma Two B Ltd.
Industry
Eligibility
35 Years to 75 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
24
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 21 more
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Study of Tau Imaging With the Use of [18F]MK-6240 Tracer

NCT04104659
Conditions
Alzheimer Disease
Interventions
MK 6240
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Myasthenia Gravis
Interventions
Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
Drug
Lead sponsor
Muscular Dystrophy Association
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Alzheimer's Disease
Interventions
Individualized management of AD including caregiver training, Memantine
Behavioral · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
New York, New York
Completed Phase 2 Interventional Results available

Effects of Tolcapone on Frontotemporal Dementia

NCT00604591
Conditions
Frontotemporal Lobar Degeneration
Interventions
Tolcapone, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
40 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
New York, New York
Conditions
Parkinson's Disease, Functional Movement Disorders, COVID-19
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Not applicable Interventional Results available

Decisions About Cancer Screening in Alzheimer's Disease

NCT03282097
Conditions
Cancer, Breast, Alzheimer Disease
Interventions
DECAD decision aid, Home safety guide
Behavioral · Other
Lead sponsor
Indiana University
Other
Eligibility
75 Years and older · Female only
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
5
States / cities
Fort Wayne, Indiana • Indianapolis, Indiana • Boston, Massachusetts
Conditions
Huntington Disease
Interventions
Not listed
Lead sponsor
Jordan Schultz
Other
Eligibility
18 Years and older
Enrollment
1,700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2025
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Friedreich Ataxia, Cardiomyopathy, Secondary
Interventions
Low dose LX2006, Mid Dose LX2006, High Dose LX2006
Genetic
Lead sponsor
Lexeo Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
3
States / cities
Los Angeles, California • Tampa, Florida • Rochester, Minnesota
Conditions
Depression
Interventions
Transcranial magnetic Stimulator
Device
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Decatur, Georgia
Conditions
Parkinson Disease
Interventions
Digital music therapeutic, Active-Control
Device · Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
40 Years to 85 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Parkinson's Disease
Interventions
Skill-Based Exercise, Aerobic Exercise, Social Contact
Other
Lead sponsor
University of Southern California
Other
Eligibility
30 Years to 85 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Blepharoptosis, Ptosis, Eyelid, Myasthenia Gravis, Stroke, Traumatic Brain Injury, Chronic Progressive External Ophthalmoplegia
Interventions
Magnetic Levator Prosthesis (MLP), Kinesiotape Frontalis Sling (KTFS)
Device
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
5 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Schizophrenia, Alzheimer Disease
Interventions
Placebo matching BI 409306 25 mg, Placebo matching BI 409306 50 mg, BI 409306 25 mg, BI 409306 50 mg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
3
States / cities
La Jolla, California • Eatontown, New Jersey • Austin, Texas
Conditions
Alzheimer Disease, Early Onset
Interventions
Cognitive Training, Tai Chi- Qi Gong, Brain Games, Stretching
Device · Behavioral
Lead sponsor
Indiana University
Other
Eligibility
40 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Alzheimer Disease (AD)
Interventions
[18F]GTP1, [18F]PI-2620, [18F]MK-6240
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Preclinical Alzheimer's Disease, Alzheimer Disease, Prodromal Alzheimer's Disease
Interventions
AADvac1, Tau2
Drug
Lead sponsor
Paul S. Aisen
Other
Eligibility
50 Years to 80 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Phoenix, Arizona • San Francisco, California • Lexington, Kentucky + 4 more
Conditions
Neurofibromatosis Type 1
Interventions
Selumetinib granule formulation, Selumetinib capsule formulation
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
1 Year to 6 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
4
States / cities
Akron, Ohio • Philadelphia, Pennsylvania • Houston, Texas + 1 more
Conditions
Major Depressive Disorder, Alzheimer Disease, Dementia, Nervous System Diseases, Memory Disorders, Depressive Disorder
Interventions
Transcranial direct current stimulation (tDCS); Transcranial alternating current stimulation (tACS)
Device
Lead sponsor
Hebrew SeniorLife
Other
Eligibility
55 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Alzheimer's Disease
Interventions
Dimebon, Placebo
Drug
Lead sponsor
Medivation, Inc.
Industry
Eligibility
50 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
4
States / cities
Los Alamitos, California • National City, California • Delray Beach, Florida + 1 more